Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $53.08 million. The enterprise value is -$21.20 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BRNS has 40.83 million shares outstanding. The number of shares has increased by 3.39% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 40.83M |
| Shares Change (YoY) | +3.39% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 24.20% |
| Float | 35.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.48 |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.89, with a Debt / Equity ratio of 0.12.
| Current Ratio | 7.89 |
| Quick Ratio | 7.17 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,000.35 |
Financial Efficiency
Return on equity (ROE) is -53.61% and return on invested capital (ROIC) is -23.79%.
| Return on Equity (ROE) | -53.61% |
| Return on Assets (ROA) | -21.35% |
| Return on Invested Capital (ROIC) | -23.79% |
| Return on Capital Employed (ROCE) | -46.23% |
| Revenue Per Employee | $142,562 |
| Profits Per Employee | -$661,200 |
| Employee Count | 105 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -47,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.75% in the last 52 weeks. The beta is -0.70, so BRNS's price volatility has been lower than the market average.
| Beta (5Y) | -0.70 |
| 52-Week Price Change | -12.75% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 116,830 |
Short Selling Information
| Short Interest | 34,250 |
| Short Previous Month | 123,092 |
| Short % of Shares Out | 0.13% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.15 |
Income Statement
In the last 12 months, BRNS had revenue of $14.97 million and -$69.43 million in losses. Loss per share was -$1.73.
| Revenue | 14.97M |
| Gross Profit | 14.44M |
| Operating Income | -54.02M |
| Pretax Income | -69.55M |
| Net Income | -69.43M |
| EBITDA | -50.28M |
| EBIT | -54.02M |
| Loss Per Share | -$1.73 |
Full Income StatementBalance Sheet
The company has $86.26 million in cash and $11.99 million in debt, giving a net cash position of $74.27 million or $1.82 per share.
| Cash & Cash Equivalents | 86.26M |
| Total Debt | 11.99M |
| Net Cash | 74.27M |
| Net Cash Per Share | $1.82 |
| Equity (Book Value) | 102.48M |
| Book Value Per Share | 2.54 |
| Working Capital | 87.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.12 million and capital expenditures -$429,000, giving a free cash flow of -$38.55 million.
| Operating Cash Flow | -38.12M |
| Capital Expenditures | -429,000 |
| Free Cash Flow | -38.55M |
| FCF Per Share | -$0.94 |
Full Cash Flow StatementMargins
| Gross Margin | 96.46% |
| Operating Margin | -360.87% |
| Pretax Margin | -464.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.39% |
| Shareholder Yield | -3.39% |
| Earnings Yield | -130.81% |
| FCF Yield | -72.64% |
Analyst Forecast
The average price target for BRNS is $3.00, which is 130.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 130.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BRNS has an Altman Z-Score of -2.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.48 |
| Piotroski F-Score | 1 |
